Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Imprimis Pharma Acquires Rights to Proprietary Sedation Formulations from Vance Thompson Vision 13
Imprimis Pharma Acquires Intellectual Property For Ophthalmic Compound Development 14
Imprimis Pharma Acquires Intellectual Property Assets From Buderer Drug Company 15
Licensing Agreements 16
Eton Pharma Receives Rights of CT-100 from Imprimis Pharma 16
Imprimis Pharma Enters into Licensing Agreement with Richard L. Lindstrom 17
Imprimis Pharma Enters into License Agreement with Urigen Pharma 18
Imprimis Pharmaceuticals Enters into Licensing Agreement with Advanced Dosage Forms 20
Imprimis Pharma Enters Into Licensing Agreement With ResolutionMD For Cosmeceutical Products 21
Equity Offering 22
Imprimis Pharma Raises USD0.2 Million in Private Placement of Shares, upon Exercise of Warrants 22
Imprimis Pharma Raises USD3 Million in Private Placement of Shares 23
Imprimis Pharma Files Registration Statement for Public Offering of Shares 24
Imprimis Pharma to Raise USD10 Million in Private Placement of Units 25
Imprimis Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD12 Million 26
Imprimis Pharma to Raise up to USD10 Million in Public Offering of Shares 28
Imprimis Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$11.1 Million 29
Imprimis Pharma Completes Private Placement Of Units For US$8 Million 30
Debt Offering 31
Imprimis Pharma Raises USD3 Million in Private Placement of 8% Note Due 2021 31
Asset Transactions 32
Imprimis Pharma Sells Pennsylvania Facility and Sinus Assets 32
Acquisition 33
Imprimis Pharmaceuticals Acquires JT Pharmacy for USD0.42 Million 33
Imprimis Pharma Acquires South Coast Specialty Compounding 34
Professional Compounding Centers of America Acquires Minority Stake In Imprimis Pharma For US$4 Million 35
Imprimis Pharmaceuticals Inc – Key Competitors 36
Imprimis Pharmaceuticals Inc – Key Employees 37
Imprimis Pharmaceuticals Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Strategy And Business Planning 40
Oct 24, 2017: Imprimis Launches Surface Pharmaceuticals Subsidiary 40
Financial Announcements 41
Aug 06, 2018: Imprimis Pharmaceuticals announces second quarter 2018 results 41
May 15, 2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results 42
Mar 08, 2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results 43
Nov 14, 2017: Imprimis Pharmaceuticals Announces Third Quarter 2017 Results 44
Aug 10, 2017: Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results 46
May 10, 2017: Imprimis Pharmaceuticals Announces First Quarter 2017 Financial Results 47
Mar 21, 2017: Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results 48
Legal and Regulatory 50
Jan 24, 2018: Imprimis Pharmaceuticals Receives DEA Manufacturer Controlled Substance Registration Certificate 50
Sep 14, 2017: FDA Curcumin Investigation Supports Imprimis Statement 51
Sep 11, 2017: Imprimis Releases Statement Regarding Allergan Lawsuit 52
Sep 07, 2017: Allergan Files Suits Against Imprimis Pharmaceuticals Prescriber’s Choice and Sincerus Florida 53
Product News 54
Oct 19, 2017: Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis 54
Other Significant Developments 55
Mar 06, 2018: Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations 55
Jul 20, 2017: Imprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings 56
Feb 16, 2017: Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imprimis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Imprimis Pharma Acquires Rights to Proprietary Sedation Formulations from Vance Thompson Vision 13
Imprimis Pharma Acquires Intellectual Property For Ophthalmic Compound Development 14
Imprimis Pharma Acquires Intellectual Property Assets From Buderer Drug Company 15
Eton Pharma Receives Rights of CT-100 from Imprimis Pharma 16
Imprimis Pharma Enters into Licensing Agreement with Richard L. Lindstrom 17
Imprimis Pharma Enters into License Agreement with Urigen Pharma 18
Imprimis Pharmaceuticals Enters into Licensing Agreement with Advanced Dosage Forms 20
Imprimis Pharma Enters Into Licensing Agreement With ResolutionMD For Cosmeceutical Products 21
Imprimis Pharma Raises USD0.2 Million in Private Placement of Shares, upon Exercise of Warrants 22
Imprimis Pharma Raises USD3 Million in Private Placement of Shares 23
Imprimis Pharma Files Registration Statement for Public Offering of Shares 24
Imprimis Pharma to Raise USD10 Million in Private Placement of Units 25
Imprimis Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD12 Million 26
Imprimis Pharma to Raise up to USD10 Million in Public Offering of Shares 28
Imprimis Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$11.1 Million 29
Imprimis Pharma Completes Private Placement Of Units For US$8 Million 30
Imprimis Pharma Raises USD3 Million in Private Placement of 8% Note Due 2021 31
Imprimis Pharma Sells Pennsylvania Facility and Sinus Assets 32
Imprimis Pharmaceuticals Acquires JT Pharmacy for USD0.42 Million 33
Imprimis Pharma Acquires South Coast Specialty Compounding 34
Professional Compounding Centers of America Acquires Minority Stake In Imprimis Pharma For US$4 Million 35
Imprimis Pharmaceuticals Inc, Key Competitors 36
Imprimis Pharmaceuticals Inc, Key Employees 37
Imprimis Pharmaceuticals Inc, Subsidiaries 38
List of Figures
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer